Developing a new drug for the treatment of ALT-positive cancers
Dr Jon Elkins and Dr Anna Rose at the University of Oxford hope to develop a new drug which will affect vital ALT-positive cancer cell processes.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Dr Jon Elkins and Dr Anna Rose at the University of Oxford hope to develop a new drug which will affect vital ALT-positive cancer cell processes.
Professor John Anderson at University College London hopes to develop a cost-effective CAR T-cell combination therapy.
Professor John Anderson’s team at University College London Great Ormond Street Institute of Child Health aim to revolutionise CAR T-cell therapy for solid tumours.
Dr Jess Morgan at the University of York hopes to understand what we already know about using portable chemotherapy pumps for children with cancer.
It is particularly difficult to treat some groups of childhood cancer patients, especially infants in their first weeks of life. This application is to fund this rapidly developing research programme for two years, involving the treatment of 150-200.
Looking at how cancer cells alter the scaffolding inside the body that organises cells in order to spread and make new tumours.
Creating an immunotherapy that can be delivered to patients more quickly and cost-effectively.
Testing a new type of targeted treatment that applies to multiple types of childhood cancers.
Testing medicines that can correct the genetic messages that help cancer cells grow out of control.